Huiyong Pharma Completes Over RMB 100 Million Series B Financing to Advance Innovative Drug Formulation Pipeline

VCBeat has learned that Whittlong Pharmaceutical Institute, a portfolio company of the Shanghai Biomedical Fund, has announced the completion of its Series B financing round, exceeding RMB 100 million. This round was jointly invested by multiple family offices.

Whittlong Pharmaceutical Research, established in May 2018, specializes in the research and development of improved novel drugs. It possesses multiple key technology platforms for advanced drug delivery systems, with its R&D focus on anti-tumor agents, analgesics, cardiovascular and cerebrovascular drugs, and pediatric medications. Its product portfolio encompasses various high-end formulations, including targeted peptide-drug conjugates, long-acting injectables, nanocrystals, polymeric micelles, novel inhalation formulations, and sustained/controlled-release preparations.Shanghai Whittlong Pharmaceutical Institute’s independently developed nanomicelle technology, targeted peptide-drug conjugate technology, and novel inhalation drug delivery technology are all internationally leading. Currently, one Class 1 new drug and four Class 2 new drugs are in clinical trials, and one generic drug has obtained production approval.

In July 2021, Shanghai Whittlong Pharmaceutical Institute established a wholly-owned subsidiary, Shanghai Whittlong Pharmaceutical Co., Ltd., primarily to undertake the industrialization of products developed by its parent company. Covering an area of 28 mu with a total construction area of 30,000 square meters, Shanghai Whittlong Pharmaceutical operates one production line for complex cytotoxic injections, one production line for complex hormonal injections, and one multi-purpose workshop for oral solid dosage forms.The company was selected as a key enterprise in Shanghai’s “Zhangjiang R&D + Shanghai Manufacturing” initiative and received special support from both municipal and district-level authorities.

Dr. Wang Hao, Founder and Chairman of Whittlong Pharmaceutical Institutestated: “We extend our sincere gratitude to the Shanghai Biopharmaceutical Fund and other existing shareholders for their care and support of Whittlong, and we also deeply appreciate the recognition and backing from the new investors participating in this round. This financing will further strengthen the company’s R&D and industrialization capabilities in the field of pharmaceutical formulations. Through our efforts, we aim to enable China to master core technologies in formulation development and transform more scientific achievements into commercially viable drugs.”